Across TCGA pan-cancer cohorts, C20orf96 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated C20orf96 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher C20orf96 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated C20orf96 expression acts as an unfavorable survival marker.

CESC, BLCA, and SKCM are the cancer types where C20orf96 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.053	0.786	<.001	30	view →
BLCA	OS	Median	IV	0.074	0.599	<.001	12	view →
SKCM	DFS	Median	All	0.015	0.758	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: C20orf96 tumor-vs-normal RNA expression · all C20orf96 data types